Advertisement
U.S. markets close in 5 minutes
  • S&P 500

    5,078.42
    +8.89 (+0.18%)
     
  • Dow 30

    38,977.20
    -92.03 (-0.24%)
     
  • Nasdaq

    16,033.45
    +57.20 (+0.36%)
     
  • Russell 2000

    2,056.43
    +27.46 (+1.35%)
     
  • Crude Oil

    78.72
    +1.14 (+1.47%)
     
  • Gold

    2,039.40
    +0.50 (+0.02%)
     
  • Silver

    22.48
    -0.05 (-0.23%)
     
  • EUR/USD

    1.0848
    -0.0005 (-0.04%)
     
  • 10-Yr Bond

    4.3150
    +0.0160 (+0.37%)
     
  • dólar/libra

    1.2682
    -0.0005 (-0.04%)
     
  • USD/JPY

    150.4740
    -0.1780 (-0.12%)
     
  • Bitcoin USD

    56,879.54
    +2,195.29 (+4.01%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,683.02
    -1.28 (-0.02%)
     
  • Nikkei 225

    39,239.52
    +5.81 (+0.01%)
     

Nemaura Medical First Half 2024 Earnings: US$0.13 loss per share (vs US$0.33 loss in 1H 2023)

Nemaura Medical (NASDAQ:NMRD) First Half 2024 Results

Key Financial Results

  • Net loss: US$3.81m (loss narrowed by 52% from 1H 2023).

  • US$0.13 loss per share (improved from US$0.33 loss in 1H 2023).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nemaura Medical Earnings Insights

Looking ahead, revenue is forecast to grow 169% p.a. on average during the next 2 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 9.3% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 8 warning signs for Nemaura Medical (6 are a bit unpleasant) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Advertisement